These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 7237468)

  • 21. The distribution of [3H]vinblastine in tumor and host tissues of Nb rats bearting a transplantable lymphoma which is highly sensitive to the alkaloid.
    Noble RL; Gout PW; Wijcik LL; Hebden HF; Beer CT
    Cancer Res; 1977 May; 37(5):1455-60. PubMed ID: 856464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay.
    Lelievre E; Guillaudeux J; Cardona H; Bourguignat A; Lokiec F; Solere P; Lucas C; Sauveur C
    Cancer Res; 1993 Aug; 53(15):3536-40. PubMed ID: 8339259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats.
    Rahmani R; Guéritte F; Martin M; Just S; Cano JP; Barbet J
    Cancer Chemother Pharmacol; 1986; 16(3):223-8. PubMed ID: 3698163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase of cyclic adenosine 3':5'-monophosphate concentration in transplantable lymphoma cells by vinca alkaloids.
    Kotani M; Koizumi Y; Yamada T; Kawasaki A; Akabane T
    Cancer Res; 1978 Sep; 38(9):3094-9. PubMed ID: 209896
    [No Abstract]   [Full Text] [Related]  

  • 25. Cellular pharmacokinetics of vinblastine and other vinca alkaloids in MO4 cells.
    Van Belle SJ; De Smet MC; De Mey JE; Storme GA
    Anticancer Res; 1991; 11(1):465-71. PubMed ID: 2018383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity of deacetyl vinblastine amide sulfate (vindesine) in rodents and mitotic accumulation studies in culture.
    Sweeney MJ; Boder GB; Cullinan GJ; Culp HW; Daniels WD; Dyke RW; Gerzon K; McMahon RE; Nelson RL; Poore GA; Todd GC
    Cancer Res; 1978 Sep; 38(9):2886-91. PubMed ID: 679195
    [No Abstract]   [Full Text] [Related]  

  • 27. A study of the cross-resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse. A report for Children's Cancer Study Group.
    Krivit W; Anderson J; Chilcote R; Pyesmany A; Chard R; Hammond D
    Am J Pediatr Hematol Oncol; 1980; 2(3):217-21. PubMed ID: 7001942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
    Lobert S; Frankfurter A; Correia JJ
    Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.
    Chello PL; Sirotnak FM
    Cancer Treat Rep; 1981; 65(11-12):1049-53. PubMed ID: 7296551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effects of vindesine, vinblastine, and vincristine on mitotic arrest and hormonal response of L1210 leukemia cells.
    Howard SM; Theologides A; Sheppard JR
    Cancer Res; 1980 Aug; 40(8 Pt 1):2695-700. PubMed ID: 6248211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension.
    Zhou XJ; Placidi M; Rahmani R
    Anticancer Res; 1994; 14(3A):1017-22. PubMed ID: 8074443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Collateral sensitivity of a methotrexate-resistant L1210 cell line to the vinca alkaloids.
    Poppitt DG; McGown AT; Fox BW
    Cancer Chemother Pharmacol; 1984; 13(1):43-6. PubMed ID: 6733841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and metabolism of Navelbine.
    Krikorian A; Rahmani R; Bromet M; Bore P; Cano JP
    Semin Oncol; 1989 Apr; 16(2 Suppl 4):21-5. PubMed ID: 2652317
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetics and metabolism of vinca alkaloids.
    Rahmani R; Zhou XJ
    Cancer Surv; 1993; 17():269-81. PubMed ID: 8137344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic selectivity of vinca alkaloids: a role for guanosine 5'-triphosphate?
    Houghton PJ; Houghton JA; Bowman LC; Hazelton BJ
    Anticancer Drug Des; 1987 Oct; 2(2):165-79. PubMed ID: 3329524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A presumed transient hemolytic reaction following vinca alkaloids administration in patients with hematological malignancies].
    Iwata N; Wakamatsu E; Oike S; Umegae S; Omine M; Maekawa T; Tsuchiya J
    Rinsho Ketsueki; 1984 May; 25(5):649-54. PubMed ID: 6590896
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro antagonism between cisplatin and vinca alkaloids.
    Lee K; Tanaka M; Kanamaru H; Hashimura T; Yamamoto I; Konishi J; Kuze F
    Br J Cancer; 1989 Jan; 59(1):36-41. PubMed ID: 2757923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of vinblastine analogues with tubulin.
    Zavala F; Guénard D; Potier P
    Experientia; 1978 Nov; 34(11):1479-9. PubMed ID: 720478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of the clinical neurotoxicity of the vinca alkaloids vincristine, vinblastine, and vindesine with their effects on cultured rat midbrain cells.
    King KL; Boder GB
    Cancer Chemother Pharmacol; 1979; 2(4):239-42. PubMed ID: 455582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Snail neurons as a possible model for testing neurotoxic side effects of antitumor agents: paracrystal formation by Vinca alkaloids.
    Müller LJ; Moorer-van Delft CM; Roubos EW
    Cancer Res; 1988 Dec; 48(24 Pt 1):7184-8. PubMed ID: 3191492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.